Versant Venture Management, LLC
CIK 0001560009 · SAN FRANCISCO, CA · Quarter end: 2026-06-30 · Filed on: 2026-08-12 · Open the SEC source ↗
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$162.6M
2026 Q2
Positions
8
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
100.0%
Est. Net Flow (Q)
—
2026 Q2
Top Holdings
GLUE
Monte Rosa Therapeutics, Inc.
47.3%
IPSC
Century Therapeutics, Inc.
18.3%
JBIO
Jade Biosciences, Inc.
13.6%
LENZ
Lenz Therapeutics, Inc.
9.3%
CTNM
Contineum Therapeutics, Inc.
5.5%
CRSP
CRISPR Therapeutics AG
5.0%
83086J200
Skye Bioscience, Inc.
0.9%
OVASUSD
Tempest Therapeutics, Inc.
0.2%
New / Increased
No prior quarter data
Reduced / Exited
No prior quarter data
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.